# Pizarra — PT-pseudo_36c92fb424ac (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_36c92fb424ac
Task: 1

Encounter: Urology - outpatient on 20 Jan 2025.
Referrer: Dr. K. Bakker (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.0 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 1.32 ng/mL/yr
  - Prior PSA: 5.4 ng/mL
  - Prostate volume: 79.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7697653 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Chronic kidney disease, Obesity (BMI >30), Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Chronic kidney disease, Obesity (BMI >30), Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: atorvastatin, simvastatin, rosuvastatin, paracetamol PRN, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 6 ng/mL. PI-RADS 4. PSAD 0.08. Prostate volume 79 mL. csPCa 0.77.

Vitals: weight 94 kg, height 184 cm, BMI 27.8, BP 123/65 mmHg, HR 58 bpm. Smoking: Ex-smoker (36 pack-yr, quit 2005).

Chief complaint: Ongoing PSA elevation combined with a previous negative biopsy necessitates clinical reassessment.

History: Initial evaluation for elevated PSA began in late 2022. This 67-year-old gentleman has completed a negative biopsy and returns now for reassessment. A retired police officer, he is married and resides alone. He walks daily for 45 minutes and abstains completely from alcohol. Lower urinary tract symptoms (IPSS 19/35) remain moderate and are effectively managed with tamsulosin. His active medications consist of atorvastatin, simvastatin, rosuvastatin, paracetamol PRN, and tamsulosin. Comorbidities include hypercholesterolaemia, chronic kidney disease, obesity (BMI >30), osteoarthritis, and benign prostatic hyperplasia. He quit smoking in 2005 after a 36 pack-year history. He completed a six-session physiotherapy regimen for stable lower back discomfort that holds no relation to his urological concerns. Routine podiatry visits maintain his foot health. Residing over 90 minutes from the facility, he favours telephone consultations when medically suitable.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: absent. The gland appears symmetrically enlarged without palpable nodules. General assessment remains unremarkable. Vital signs are stable. There are no clinical indicators of systemic disease or lymphadenopathy.

Patient info: retired police officer; Married; Lives alone.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 45 min/day; IPSS score: 19/35 (moderate LUTS).

Recent other appointments: Podiatry — routine foot care; Physiotherapy — lower back, six sessions.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.60 +/- 0.21   (95% CI 0.17-0.94)

Where the uncertainty comes from:
  - aleatoric  dA = 0.18  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.10  (few labelled cases resemble this one)
  - 4.0 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=1.0, psa=6.0, age=67.0, psad=0.08, dre_ord=0.0, vol=79.0, n_pmhx=5.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the PSA velocity (1.32 ng/mL/yr) or the PSA trend (prior PSA 5.4 ng/mL), which indicate a rising trend, against the PI-RADS 4 score and the prior negative biopsy status. It also missed the context provided by the laboratory panel and the full mpMRI report, which are crucial for assessing the lesion characteristics.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests BIOPSY with a wide interval (0.17-0.94). This wide interval suggests the classifier is uncertain. A failure mode is the contradiction between the high csPCa predicted probability (0.77) and the prior negative biopsy status, which might make the question "does he have cancer" inappropriate. Another failure mode is the DRE being 'Normal' despite a PSA of 6.0 and PI-RADS 4, which could be an internal contradiction that the prior did not resolve.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details high-risk features (e.g., volume, extension) or specific lesion characteristics, it would refine the PI-RADS 4 assessment.
  <document> PSA history (trend) -> If the trend is significantly increasing, it would increase the urgency for further investigation despite the prior negative biopsy.
  <document> laboratory results (full panel) -> If the lab panel shows any markers (e.g., inflammation, renal function changes) that might influence the risk stratification.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the initial evaluation or any specific clinical concerns not captured in the structured panel.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_36c92fb424ac", "radiology_report": "Subject: Multiparametric MRI Prostate | Date: 15 Jan 2025 | Institution: Catharina Ziekenhuis (Eindhoven)\n\nClinical Context:\nA 67-year-old gentleman with a PSA reading of 6.0 ng/mL and a history of a negative biopsy warrants re-evaluation due to a rising PSA trajectory and clinical suspicion of clinically significant prostate cancer.\n\nImaging Characteristics:\nThe gland occupies 79.0 mL of volume. T2-weighted sequences highlight a focal hypointense abnormality, roughly 18 mm, situated in the right peripheral zone at mid-gland height. Diffusion-weighted imaging shows pronounced restriction with matching low apparent diffusion coefficient signal. Dynamic contrast phases capture early, focal enhancement compared to adjacent parenchyma. Seminal vesicles remain clear; no capsular breach or suspicious nodal enlargement is evident.\n\nIMPRESSION:\nPI-RADS 4 lesion in the right peripheral zone mid-gland.\nProstate volume 79.0 mL; PSA density 0.08 ng/mL/mL.\ncsPCa predicted probability 0.7697653."}

  **psa_trend**
  {"case_id": "PT-pseudo_36c92fb424ac", "psa_trend": [{"date": "Nov 2023", "val": 2.5}, {"date": "Jun 2024", "val": 1.4}, {"date": "Jan 2025", "val": 6.0}]}

  **lab_results**
  {"case_id": "PT-pseudo_36c92fb424ac", "laboratory_results": [{"name": "PSA", "val": "6.0 ng/mL", "date": "09 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "0.72 ng/mL", "date": "09 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "12%", "date": "09 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "15.2 g/dL", "date": "09 Dec 2024", "flag": ""}, {"name": "WBC", "val": "8.4 x10^9/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "195 x10^9/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "137 umol/L", "date": "09 Dec 2024", "flag": "H"}, {"name": "eGFR", "val": "<60 mL/min/1.73m2", "date": "09 Dec 2024", "flag": "L"}, {"name": "Testosterone", "val": "11.5 nmol/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "86 U/L", "date": "09 Dec 2024", "flag": ""}, {"name": "LDH", "val": "167 U/L", "date": "09 Dec 2024", "flag": ""}]}

  **previous_notes**
  {"case_id": "PT-pseudo_36c92fb424ac", "previous_notes": [{"date": "31 Jan 2023", "author": "Dr. K. Bakker (GP)", "text": "Initial laboratory screening identified a PSA level of 3.9 ng/mL. Digital palpation showed no abnormalities. A multiparametric MRI was ordered to evaluate potential suspicious areas. After reviewing the risks associated with a biopsy, the patient opted to pursue imaging first."}, {"date": "26 Jan 2024", "author": "Dr. K. Bakker (GP)", "text": "Subsequent laboratory analysis conducted in June 2024 indicated a PSA rise to 5.4 ng/mL. Earlier imaging had identified a PI-RADS 4 lesion, prompting a systematic biopsy that ultimately yielded negative results for cancer. Owing to the sustained PSA elevation alongside those radiological markers, the individual is being redirected to urology for further assessment."}]}

WHAT THE EVIDENCE SUPPORTS
  findings that argue FOR sampling this patient now:
  PSA: 6.0 ng/mL
  PSA velocity: 1.32 ng/mL/yr (rising trend)
  mpMRI: PI-RADS 4 lesion in the right peripheral zone mid-gland
  csPCa predicted probability: 0.7697653

  findings that argue AGAINST sampling this patient now:
  Prior biopsy: Negative

WHERE THIS LEANS
  The evidence strongly argues for further investigation due to the combination of a high PI-RADS score (4), a rising PSA velocity, and a high predicted csPCa probability (0.77), which contradicts the prior negative biopsy. This leans towards recommending a repeat biopsy or further active surveillance based on current guidelines for high-risk findings.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

A repeat biopsy is recommended because the patient presents with a PI-RADS 4 lesion, a rising PSA velocity of 1.32 ng/mL/yr, and a high csPCa predicted probability of 0.77, which strongly contradicts the prior negative biopsy. The combination of these high-risk features warrants further tissue sampling to re-evaluate the management plan.

Variables that carried weight: bx=decisive, age=noted, psa=decisive, vol=important, psad=important, cspca=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
